Düsseldorf, Tokyo, and New York In October 2024, Asahi Kasei Medical introduced the PlanovaTM FG1, a next-generation viral elimination filter with increased flow for biotherapeutics manufacturing.
PlanovaTM virus elimination filters and equipment utilised in the production of biotherapeutic products, including biopharmaceuticals and plasma derivatives, as well as biosafety testing services, are all part of Asahi Kasei Medical’s bioprocess business. CDMO activities. It is one of the companies of the Asahi Kasei Group that will propel its future expansion.
With the introduction of PlanovaTM BioEX hydrophilic PVDF hollow-fiber membrane filters in 2009 and PlanovaTM S20N next-generation cellulose hollow-fiber membrane filters in 2022, the company, which has been in business since 1989, increased the range of products it offers to suit the increased requirements for the virus worldwide safety of biotherapeutics. As the demand for monoclonal antibodies and other biopharmaceuticals continues to rise by 5–10% annually, the new PlanovaTM FG1 is anticipated to further contribute to increased productivity.
PlanovaTM FG1, which was created to increase efficiency in the biopharmaceutical manufacturing process, has excellent performance in terms of filtration speed and virus elimination robustness. Virus filtering time is made possible by its high flux, which is around seven times that of PlanovaTM BioEX.
to be shortened, and when the filtering process is stopped, there is a lower chance of a virus breaking out.
Even without a prefilter to remove aggregates, customer assessment during the PlanovaTM FG1 development stage verified good protein filtration and virus elimination performance under a variety of situations using several solutions. PlanovaTM FG1 may be utilised with a wide range of current biopharmaceutical production equipment since it is also compatible with normal cleaning in place (CIP) and sterilisation in place (SIP) procedures.
In order to help its clients effectively scale up their processes, Asahi Kasei Medical will progressively expand the product selection with additional filters with bigger surface areas after the October 2024 commencement of mass production and distribution of smaller filters of PlanovaTM FG1. PlanovaTM FG1 has been added to its With its wide range of solutions, Asahi Kasei Medical will help biopharmaceutical producers better establish the PlanovaTM brand and make pharmaceutical production safer and more effective.
Asahi Kasei Medical President Ken Shinomiya stated, “Asahi Kasei Medical is excited to introduce the PlanovaTM FG1 next-generation virus removal filter.” “We are eager to keep assisting biopharmaceutical producers with our extensive and expanding range of goods that enable them to produce medications in a safe and effective manner that patients can rely on.
For more information, visit https://planova.ak-bio.com/products_services/planova-FG1/.
For product inquiries, visit https://planova.ak-bio.com/campaign/fg1/.
About Asahi Kasei
The Asahi Kasei Group contributes to life and living for people around the world. Since its founding in
1922 with ammonia and cellulose fiber businesses, Asahi Kasei has consistently grown through the
proactive transformation of its business portfolio to meet the evolving needs of every age. With more
than 49,000 employees worldwide, the company contributes to a sustainable society by providing
solutions to the world’s challenges through its three business sectors of Material, Homes, and Health
Care. Its Material sector, comprised of Environmental Solutions, Mobility & Industrial, and Life
Innovation, includes a wide array of products from battery separators and biodegradable textiles to
engineering plastics and sound solutions. For more information, visit https://www.asahi-kasei.com/.
Asahi Kasei is also dedicated to sustainability initiatives and is contributing to reaching a carbon-
neutral society by 2050. To learn more, visit https://www.asahi-kasei.com/sustainability/.